Literature DB >> 10517465

Modified Dakin's solution for cutaneous vibrio infections.

B J Wilhelmi1, T A Calianos, E A Appelt, M E Ortiz, J P Heggers, L G Phillips.   

Abstract

Vibrio species, specifically Vibrio vulnificus, are known to be endemic to warm saltwater environments. As a human pathogen they are capable of causing severe, progressive, necrotizing infections. The lesions are bullous in nature and often require wide surgical debridement due to the aggressiveness of this organism. The literature supports prophylactic antibiotic therapy for those with preexisting hepatic dysfunction or immunocompromise. The authors routinely implement prophylactic antibiotic coverage with doxycycline 100 mg every 12 hours for vibrio in patients with wounds exposed to or acquired in saltwater. In addition, they institute topical therapy with 0.025% sodium hypochlorite solution (modified Dakin's), based on their in vitro study of vibrio sensitivity to antimicrobials. Over the past 2 years, the authors have treated 10 patients with this protocol for cutaneous vibrio infections confirmed by quantitative cultures. None of these patients experienced progression of infection requiring operative debridement-contrary to the aggressive nature of this organism documented in other reports.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517465     DOI: 10.1097/00000637-199910000-00007

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  3 in total

1.  Two cases of severe sepsis due to Vibrio vulnificus wound infection acquired in the Baltic Sea.

Authors:  J Ruppert; B Panzig; L Guertler; P Hinz; G Schwesinger; S B Felix; S Friesecke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-12       Impact factor: 3.267

2.  Further characterization of Vibrio vulnificus rugose variants and identification of a capsular and rugose exopolysaccharide gene cluster.

Authors:  Brenda L Grau; Margaret C Henk; Katherine L Garrison; Brett J Olivier; Randall M Schulz; Kathy L O'Reilly; Gregg S Pettis
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

Review 3.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Authors:  Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy
Journal:  Support Care Cancer       Date:  2011-06-01       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.